FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/07/055382 [Registered on: 20/07/2023] Trial Registered Prospectively
Last Modified On: 08/02/2024
Post Graduate Thesis  No 
Type of Trial  BA/BE 
Type of Study    
Study Design  Randomized, Crossover Trial 
Public Title of Study   An open label randomised, single dose two treatment two way crossover oral bioavailability study of investigational product in healthy adult human participant under fasting conditions.  
Scientific Title of Study   An open label randomized single dose two treatment two way crossover oral bioavailability study of investigational product in healthy adult human participants under fasting conditions. 
Trial Acronym  nil 
Secondary IDs if Any  
Secondary ID  Identifier 
VCR-CSP-23/002 ver1.0 dated 25Jun2023  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ambanna Gowda 
Designation  Consultant Physician 
Affiliation  Unitree Health Care Diagnostics 
Address  Unitree Health Care Diagnostics at 38/1 Church Road Marappa Garden J C Nagar Bengaluru

Bangalore
KARNATAKA
560006
India 
Phone  9845270377  
Fax  -  
Email  unitreeclinicalresearch@gmail.com  
 
Details of Contact Person
Scientific Query  
Name  Dr Ambanna Gowda 
Designation  Consultant Physician 
Affiliation  Unitree Health Care Diagnostics 
Address  Unitree Health Care Diagnostics at 38/1 Church Road Marappa Garden J C Nagar Bengaluru


KARNATAKA
560006
India 
Phone  9845270377  
Fax  -  
Email  unitreeclinicalresearch@gmail.com  
 
Details of Contact Person
Public Query  
Name  Shalini Dayananda 
Designation  Project Manager 
Affiliation  Vivatiq Clinical Research 
Address  358/274 Srigandha Nagar Main Road Hegganahalli Vishwaneedam Post (near Peenya Industrial Area 2nd stage)

Bangalore
KARNATAKA
560079
India 
Phone  9980107723  
Fax  -  
Email  vivatiqcr@gmail.com  
 
Source of Monetary or Material Support  
Unitree Health Care Diagnostics 38/1, Church Road, Marappa Garden, J C Nagar, Bengaluru 560006, Karnataka, India.  
 
Primary Sponsor  
Name  YourZooki holdings Ltd  
Address  05 Garstang Road, Preston, Lancashire, United Kingdom, PR1 1LD. 
Type of Sponsor  Pharmaceutical industry-Global 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ambanna Gowda  Unitree Health Care Diagnostics   38/1 Church Road Marappa Garden J C Nagar Bengaluru
Bangalore
KARNATAKA 		 9845270377
-
unitreeclinicalresearch@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
ACE Independent Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  NA 
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Conventional Vitamin C Liquid  1 sachet with 1000 mg vitamin C 
Intervention  Liposomal Vitamin C Liquid  NLT 1000 mg vitamin C as Ascorbic Acid- 1 sachet  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  Normal healthy adult male and female Human participants of age between 21-65 years with a Body Mass Index (BMI) range between 18.50 kg/m2 to 24.99 kg/m2.
2.Plasma Ascorbic acid at screening <75μmol/1.
3.Subject agrees avoid vitamin C containing medications and dietary supplements from screening until last visit.
4.Subject agrees to avoid high activity physical exercise 72.00 hours prior to last visit
5.Subjects who have no evidence of underlying disease during screening and check- in and whose screening is performed within 29 days of check in.
6.Subjects whose screening laboratory values are within normal limits or considered by the physician or principal/clinical investigator to be of no clinical significance.
7.Healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital sign assessments.
8.Generally healthy as documented by 12-lead electrocardiogram (ECG), X-Ray and clinical laboratory assessments.
9.Non- smokers or ex-smokers. Ex-smokers are defined as someone who has completely stopped smoking for at least the past 03 months.
10.Willing to consume ova-lacto vegetarian diet.
11.Willing to comply to all requirements of this study protocol as well as instructed by the study personnel
12.Female subjects within normal limits or clinically non-significant laboratory evaluation results for FSH and LH.
13.Generally healthy as documented by gynecological examination and breast examination (for female subjects during Period-I check-in only).
14.Female subjects of childbearing potential;
a.Practicing an acceptable non-hormonal contraceptive method of birth control after consulting with principal investigator; and/or
b.Surgically sterile (bilateral tubal ligation)
 
 
ExclusionCriteria 
Details  1.Evidence of allergy or known hypersensitivity to Vitamin C or other related drugs or other related drugs.
2.Subjects with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver disease, alcohol abuse, existing tinnitus, renal or liver impairment and pre-existing gallbladder disease.
3.Any major illness in the last three months or any significant ongoing chronic medical illness.
4.Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, Musculoskeletal, respiratory, central nervous system, diabetes, psychosis or any other body system.
5.History of alcohol addiction or abuse.
6.Malabsorption syndrome that affects vitamin c metabolism.
7.Heart failure, angina pectoris, ventricular arrhythmias or atrial fibrillation with >100/min ventricular rate.
8.Gastrointestinal bleeding in past three months.
9.Uncontrolled diabetes mellitus.
10.Active psychiatric disorder, intention for suicidal, disorders with Unconsciousness.
11.Psychopathic disorder, lack of cooperation.
12.Chronic obstructive lung disease or active smoking (more than 2 cigarettes in the past 6 months)
13.Taking more than 100 mg vitamin C daily within 2 weeks to screening.
14.Consumption of caffeine and /or Xanthine containing products (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), tobacco containing products for at least 24.00 hours prior to check-in and throughout the entire study
15.Consumption of grapefruit and its juice and poppy containing foods for at least 72.00 hours prior to check-in and throughout the study.
16.Subjects who taken any prescription medications, over the counter medicinal products, herbal medications within 14 days prior to study check in and throughout the study.
17.History of dehydration from diarrhea, vomiting or any other reason within a period of 24.00 hours prior to study check-in of each period.
18.An unusual or abnormal diet within 48.00 hours prior to study check-in of each period, for whatever reason e.g. because of fasting due to religious reasons.
19.Subject who had participated in any other study within the 90 days of check-in.
20.History of difficulty in swallowing.
21.Positive results for drugs of abuse (Marijuana-THC, amphetamine-AMP, barbiturates-BAR, cocaine-COC, benzodiazepines-BZD and morphine-MOR) in urine prior to check-in of this study period.
22.Positive results for alcohol breath test prior to check-in of any study period
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Pre-numbered or coded identical Containers 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
Cmax AUC0-t AUC0-infinity.  pre-dose blood sample 00.00 hours 05 ml will be collected within 60 minutes prior to dosing. Post dose blood samples 05 ml will be collected at 00.50, 01.00, 02.00, 06.00,12.00 ,24.00 & 48 hours. 
 
Secondary Outcome  
Outcome  TimePoints 
tmax, Kel, t½.  pre-dose blood sample 00.00 hours 05 ml will be collected within 60 minutes prior to dosing. Post dose blood samples 05 ml will be collected at 00.50, 01.00, 02.00, 06.00,12.00 ,24.00 & 48 hours. 
 
Target Sample Size   Total Sample Size="12"
Sample Size from India="12" 
Final Enrollment numbers achieved (Total)= "0"
Final Enrollment numbers achieved (India)="12" 
Phase of Trial   N/A 
Date of First Enrollment (India)   28/07/2023 
Date of Study Completion (India) 30/12/2023 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  		 Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Vitamin C is a water-soluble vitamin that is commonly used in food. It is utilized as an additive, because of its reducing and antioxidant properties. The usage of ascorbic acid in food is associated with a variety of biological activities such as the protection of oxidizable molecules, the retardation of enzymatic browning, oxygen scavenging, the prevention of nitrosamine production. The bioavailability and shelf life of bioactive components have both been improved by using encapsulation technology. Liposomes are vesicles that are simple models of highly complex cell membranes, consisting of lipid bilayers surrounding an aqueous core. Due to their unique biocompatibility and biodegradability, liposomes have attracted significant interest in the delivery and protection of both hydrophilic and hydrophobic compounds, such as vitamins. So liposomal encapsulated vitamin C helps to overcome the degradation of vitamin C due to high reactivity. It also improves the absorption into intestine by the controlled release of vitaminC. 
Close